Celsion Corporation Stock Nasdaq
Equities
US15117N4043
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-13 | Transcript : Imunon, Inc., Q1 2024 Earnings Call, May 13, 2024 | |
05-08 | IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 13.25M 18.02M |
---|---|---|---|---|---|
Net income 2024 * | -20M -27.2M | Net income 2025 * | -25M -34M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.72
x | P/E ratio 2025 * |
-0.55
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.85% |
Latest transcript on Celsion Corporation
Managers | Title | Age | Since |
---|---|---|---|
Stacy Lindborg
CEO | Chief Executive Officer | 53 | 21-06-03 |
Michael Tardugno
CHM | Chairman | 73 | 07-01-02 |
Jeffrey Church
DFI | Director of Finance/CFO | 67 | 10-07-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 21-06-07 | |
Frederick Fritz
BRD | Director/Board Member | 73 | 11-07-07 |
James Dentzer
BRD | Director/Board Member | 57 | 22-09-02 |
1st Jan change | Capi. | |
---|---|---|
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |